<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="143045">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02065284</url>
  </required_header>
  <id_info>
    <org_study_id>HBWP and RAS</org_study_id>
    <nct_id>NCT02065284</nct_id>
  </id_info>
  <brief_title>Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis</brief_title>
  <official_title>Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation on Walking and Cortical Activation in Patients With Multiple Sclerosis.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The Cleveland Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Eleanor and Kelvin Smith Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The Cleveland Clinic</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic
      auditory cues (like a beat) to help improve patients' movements, especially when walking.

      The purpose of this study is to compare the effect on walking performance of a home based
      walking program (HBWP) with Rhythmic Auditory Stimulation (RAS), to that of a HBWP without
      RAS, or to RAS without walking exercise.

      A second part of this study will assess the effects of Rhythmic Auditory Stimulation (RAS)
      on brain activity in patients with Multiple Sclerosis while performing mental imagery of
      walking.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>February 2014</start_date>
  <completion_date type="Anticipated">December 2015</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Improved gait pattern on gait analysis</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>To compare the effect on gait pattern of a walking program with Rhythmic Auditory Stimulation, to that of a walking program without Rhythmic Auditory Stimulation, or Rhythmic Auditory Stimulation without walking exercise.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improved walk time on the timed 25 foot walk test</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the effect on walking performance of a walking program with Rhythmic Auditory Stimulation, to that of a walking program without Rhythmic Auditory Stimulation, or Rhythmic Auditory Stimulation without walking exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improved distance on the 2 minute walk test</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>To compare the effect on walking performance of a walking program with Rhythmic Auditory Stimulation, to that of a walking program without Rhythmic Auditory Stimulation, or Rhythmic Auditory Stimulation without walking exercise.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To assess changes in cortical activation induced by Rhythmic Auditory Stimulation in Multiple Sclerosis patients performing mental imagery of walking.</measure>
    <time_frame>8 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Collect functional MRI images while performing guided imagery.</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Multiple Sclerosis</condition>
  <condition>Ambulation Difficulty</condition>
  <arm_group>
    <arm_group_label>Walking-Rhythmic Auditory Stimulation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Walking  daily with Rhythmic Auditory Stimulation (RAS) based music for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Walking- only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Walking daily with no  Rhythmic Auditory Stimulation (RAS) based music for 4 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhythmic Auditory Stimulation (RAS)only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Listening to  based music only daily for 4 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Rhythmic Auditory Stimulation (RAS)</intervention_name>
    <description>Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.</description>
    <arm_group_label>Walking-Rhythmic Auditory Stimulation</arm_group_label>
    <arm_group_label>Walking- only</arm_group_label>
    <arm_group_label>Rhythmic Auditory Stimulation (RAS)only</arm_group_label>
    <other_name>RAS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. age 18 years or older

          2. diagnosis of MS per Mc Donald criteria

          3. Ambulation Index score from 2 to 6 inclusive (clinically observable gait disturbance,
             whether the subject walks with no, unilateral, or bilateral support)

          4. spastic paresis is the main neurologic impairment causing the gait disturbance, per
             investigator's judgment.

        Exclusion Criteria:

          1. neurologic impairments other than spastic paresis (e.g. cerebellar ataxia or sensory
             ataxia), or non-neurologic impairments (e.g. musculoskeletal problems) play a major
             role in the subject's gait disturbance, per investigator's judgment;

          2. treatment for an MS exacerbation in the past 30 days;

          3. severe co morbidity precluding participation in the study per investigator's judgment
             (e.g. severe cardiac or respiratory failure);

          4. severe cognitive deficits precluding informed consent or preventing the subject from
             following study procedures safely

          5. contraindication to MRI such as severe claustrophobia and implanted devices such as
             neurostimulators, pacemakers, aneurysm clips etc.

          6. pregnancy.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francois A Bethoux, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Darlene K. Stough, RN</last_name>
    <phone>216-445-5877</phone>
    <email>stoughd@ccf.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Diane Ivancic</last_name>
    <phone>216-444-5441</phone>
    <email>ivancid@ccf.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cleveland Clinic Neurological Institute Mellen Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Darlene K Stough, RN</last_name>
      <phone>216-445-5877</phone>
      <email>stoughd@ccf.org</email>
    </contact>
    <contact_backup>
      <last_name>Diane Ivancic</last_name>
      <phone>216-444-5441</phone>
      <email>ivancid@ccf.org</email>
    </contact_backup>
    <investigator>
      <last_name>Francois A Bethoux, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 13, 2014</lastchanged_date>
  <firstreceived_date>February 13, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MS</keyword>
  <keyword>Ambulation</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Mobility Limitation</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
